PLUS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.27 USD | +6.57% |
|
+31.98% | +29.71% |
Presenter SpeechMarc Hedrick (Executives)Good morning, ladies and gentlemen. I am Marc Hedrick...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.27
USD
Average target price
16.5
USD
Spread / Average Target
+626.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.71% | 9.11M | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
- Stock Market
- Equities
- PSTV Stock
- News Plus Therapeutics, Inc.
- Transcript : Plus Therapeutics, Inc. - Shareholder/Analyst Call